4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine has been researched along with u 69593 in 1 studies
| Studies (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Trials (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Recent Studies (post-2010) (4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine) | Studies (u 69593) | Trials (u 69593) | Recent Studies (post-2010) (u 69593) |
|---|---|---|---|---|---|
| 42 | 0 | 9 | 524 | 0 | 75 |
| Protein | Taxonomy | 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine (IC50) | u 69593 (IC50) |
|---|---|---|---|
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0006 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.194 | |
| Delta-type opioid receptor | Homo sapiens (human) | 3.6437 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0021 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.058 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.588 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
1 other study(ies) available for 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine and u 69593
| Article | Year |
|---|---|
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |